ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells

Coupling of Homologous Recombination and the Checkpoint by ATR

(2017) Rémi Buisson et al.   MOLECULAR CELL

The BRCA1- 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

(2016) Y. Wang et al.   CANCER RESEARCH

Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models

(2016) Hyoung Kim et al.   CLINICAL CANCER RESEARCH

ATM/ATR‐mediated phosphorylation of PALB2 promotes RAD51 function

(2016) Johanna K Ahlskog et al.   EMBO REPORTS

DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer

(2016) Daniela Kurfurstova et al.   Molecular Oncology

Replication fork stability confers chemoresistance in BRCA-deficient cells

(2016) Arnab Ray Chaudhuri et al.   NATURE

Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1 -Mutant Ovarian Cancer

(2016) Young Eun Choi et al.   Cell Reports

Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors

(2015) Christopher J. Lord et al.   Annual Review of Medicine

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

(2015) G. Kim et al.   CLINICAL CANCER RESEARCH

Resistance to therapy inBRCA2mutant cells due to loss of the nucleosome remodeling factor CHD4

(2015) Shawna Guillemette et al.   GENES & DEVELOPMENT

Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation

(2015) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the DNA Damage Response in Cancer

(2015) Mark J. O’Connor   MOLECULAR CELL

MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5′ end resection

(2015) Vera Boersma et al.   NATURE

A mechanism for the suppression of homologous recombination in G1 cells

(2015) Alexandre Orthwein et al.   NATURE

REV7 counteracts DNA double-strand break resection and affects PARP inhibition

(2015) Guotai Xu et al.   NATURE

Mammalian RAD51 paralogs protect nascent DNA at stalled forks and mediate replication restart

(2015) Kumar Somyajit et al.   NUCLEIC ACIDS RESEARCH

Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins

(2015) Rohit Prakash et al.   Cold Spring Harbor Perspectives in Biology

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model

(2015) Bhagwan Yadav et al.   Computational and Structural Biotechnology Journal

A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments

(2015) Kareem N. Mohni et al.   PLoS One

Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer

(2014) Shaohua Chen et al.   CANCER LETTERS

PTIP associates with Artemis to dictate DNA repair pathway choice

(2014) Jiadong Wang et al.   GENES & DEVELOPMENT

Phosphorylated RPA recruits PALB2 to stalled DNA replication forks to facilitate fork recovery

(2014) Anar K. Murphy et al.   JOURNAL OF CELL BIOLOGY

Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility

(2014) M. Yu et al.   SCIENCE

ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status

(2013) C. J. Huntoon et al.   CANCER RESEARCH

Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor

(2013) Hideaki Ogiwara et al.   CARCINOGENESIS

53BP1 Mediates Productive and Mutagenic DNA Repair through Distinct Phosphoprotein Interactions

(2013) Elsa Callen et al.   CELL

ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA

(2013) Luis Ignacio Toledo et al.   CELL

RIF1 Counteracts BRCA1-mediated End Resection during DNA Repair

(2013) Lin Feng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity

(2013) Kevin M. Foote et al.   JOURNAL OF MEDICINAL CHEMISTRY

ATM- and ATR-Mediated Phosphorylation of XRCC3 Regulates DNA Double-Strand Break-Induced Checkpoint Activation and Repair

(2013) Kumar Somyajit et al.   MOLECULAR AND CELLULAR BIOLOGY

RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection

(2013) J. Ross Chapman et al.   MOLECULAR CELL

A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice

(2013) Cristina Escribano-Díaz et al.   MOLECULAR CELL

PRP19 Transforms into a Sensor of RPA-ssDNA after DNA Damage and Drives ATR Activation via a Ubiquitin-Mediated Circuitry

(2013) Alexandre Maréchal et al.   MOLECULAR CELL

Mechanisms of resistance to therapies targeting BRCA-mutant cancers

(2013) Christopher J Lord et al.   NATURE MEDICINE

A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity

(2013) Stephen J. Pettitt et al.   PLoS One

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance

(2013) N. Johnson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

53BP1 Regulates DSB Repair Using Rif1 to Control 5' End Resection

(2013) M. Zimmermann et al.   SCIENCE

Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching

(2013) M. Di Virgilio et al.   SCIENCE

Mechanisms of Resistance to PARP Inhibitors—Three and Counting

(2013) Tito Fojo et al.   Cancer Discovery

The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy

(2012) Remko Prevo et al.   CANCER BIOLOGY & THERAPY

A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2

(2012) Katharina Schlacher et al.   CANCER CELL

Abstract 5588: A phase I, open label, dose escalation study of an oral mammalian target of rapamycin inhibitor INK128 administered once daily in patients with advanced malignancies

(2012) Jeffrey R. Infante et al.   CANCER RESEARCH

Abstract 2814: Potent and selective small molecule inhibitors of polo-like kinase 1: Biological characterization

(2012) Sheelagh Frame et al.   CANCER RESEARCH

BRCA1 Functions Independently of Homologous Recombination in DNA Interstrand Crosslink Repair

(2012) Samuel F. Bunting et al.   MOLECULAR CELL

A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response

(2012) Britt Adamson et al.   NATURE CELL BIOLOGY

Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors

(2012) Janneke E. Jaspers et al.   Cancer Discovery

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

(2011) A Peasland et al.   BRITISH JOURNAL OF CANCER

Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11

(2011) Katharina Schlacher et al.   CELL

Analysis of protein dynamics at active, stalled, and collapsed replication forks

(2011) B. M. Sirbu et al.   GENES & DEVELOPMENT

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR

(2011) Philip M Reaper et al.   Nature Chemical Biology

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

(2011) A. G. Patel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance

(2010) N. Issaeva et al.   CANCER RESEARCH

53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks

(2010) Samuel F. Bunting et al.   CELL

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

(2010) Peter Bouwman et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response

(2009) Feng Zhang et al.   CURRENT BIOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

PALB2 is an integral component of the BRCA complex required for homologous recombination repair

(2009) S. M. H. Sy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance

(2008) E. M. Swisher et al.   CANCER RESEARCH

A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity

(2008) Christopher J. Lord et al.   DNA REPAIR

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

(2008) Wataru Sakai et al.   NATURE

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA